-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 PyOs4llR85oW40oNvAPuwwFwHRNNrJvW49Wmi5qUEwp/bPq6bUroHlJoavq3xWI7
 zEegZ1Vg8EO7c9+qzqs+0g==

<SEC-DOCUMENT>0000950137-04-011278.txt : 20041221
<SEC-HEADER>0000950137-04-011278.hdr.sgml : 20041221
<ACCEPTANCE-DATETIME>20041221135721
ACCESSION NUMBER:		0000950137-04-011278
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20041221
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20041221
DATE AS OF CHANGE:		20041221

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EPIMMUNE INC
		CENTRAL INDEX KEY:			0000822206
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				330245076
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19591
		FILM NUMBER:		041216649

	BUSINESS ADDRESS:	
		STREET 1:		5820 NANCY RIDGE DRIVE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858-860-2500

	MAIL ADDRESS:	
		STREET 1:		5820 NANCY RIDGE DRIVE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CYTEL CORP/DE
		DATE OF NAME CHANGE:	19940324
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a04192e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>Epimmune Inc.</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<P><DIV style="position: relative; float: left; margin-right: 1%; width: 65%">

<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

</DIV>

<DIV style="border: 1px solid black; padding: 1px; position: relative; float: right; margin-left: 1%; width: 33%">

<P align="center" style="font-size: 10pt"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;OMB&nbsp;APPROVAL&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">

<!-- Begin Table Head --><TR valign="bottom">
    <TD width="60%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
</TR>

<!-- End Table Head -->

<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">OMB Number:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;3235-0060</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Expires:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">March&nbsp;31, 2006</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Estimated average burden<BR>
hours per response
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;28.0</TD>
</TR>


<!-- End Table Body -->
</TABLE>
</DIV>


</DIV>
<BR clear="all"><BR>

<P align="center" style="font-size: 10pt"><B>EFFECTIVE AUGUST 23RD, 2004</B>


<P align="center" style="font-size: 14pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>

<DIV align="center" style="font-size: 12pt"><B>Washington, D.C. 20549</B>
</DIV>

<P align="center" style="font-size: 18pt"><B>FORM 8-K</B>


<P align="center" style="font-size: 10pt"><B>CURRENT REPORT<BR>
Pursuant to Section&nbsp;13 OR 15(d) of<BR>
The Securities Exchange Act of 1934</B>



<P align="center" style="font-size: 10pt">Date of Report (Date of
earliest event reported): December&nbsp;21, 2004


<P align="center" style="font-size: 24pt"><B>EPIMMUNE INC.</B>

<DIV align="center" style="font-size: 10pt">(Exact name of registrant as specified in its charter)</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">

<!-- Begin Table Head --><TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>

<!-- End Table Head -->

<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Delaware</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>0-19591</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>33-0245076</B></TD>
</TR>

<TR valign="bottom">
    <TD align="center" valign="top">(State or other jurisdiction<BR>
of incorporation)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(Commission<BR>
File Number)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(IRS Employer<BR>
Identification No.)</TD>
</TR>


<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">

<!-- Begin Table Head --><TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>

<!-- End Table Head -->

<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>5820 Nancy Ridge Drive<BR>
San Diego, California</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom"><B>92121</B></TD>
</TR>

<TR valign="bottom">
    <TD align="center" valign="top">(Address of principal executive offices)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(Zip Code)</TD>
</TR>


<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt">Registrant&#146;s telephone number, including area code: <B>(858)&nbsp;860-2500</B>


<P align="left" style="font-size: 10pt">Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):


<P align="left" style="font-size: 10pt">&#091;&nbsp;&nbsp;&#093; Written communications pursuant to Rule&nbsp;425 under the Securities Act (17
CFR 230.425)


<P align="left" style="font-size: 10pt">&#091;&nbsp;&nbsp;&#093; Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR
240.14a-12)


<P align="left" style="font-size: 10pt">&#091;&nbsp;&nbsp;&#093; Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))


<P align="left" style="font-size: 10pt">&#091;&nbsp;&nbsp;&#093; Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))



<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<!-- TOC -->
<A name="toc"><DIV align="CENTER" style="page-break-before:always"><U><B>TABLE OF CONTENTS</B></U></DIV></A>

<P><CENTER>
<TABLE border="0" width="90%" cellpadding="0" cellspacing="0">
<TR>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="76%"></TD>
</TR>
<TR><TD></TD><TD colspan="8"><A HREF="#000">Item&nbsp;8.01 Other Events.</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#001">Item&nbsp;9.01 Financial Statements and Exhibits.</A></TD></TR>
<TR><TD colspan="9"><A HREF="#002">SIGNATURES</A></TD></TR>
<TR><TD colspan="9"><A HREF="#003">INDEX TO EXHIBITS</A></TD></TR>
<TR><TD colspan="9"><A HREF="a04192exv99w1.txt">EXHIBIT 99.1</A></TD></TR>
</TABLE>
</CENTER>
<!-- /TOC -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<!-- link2 "Item&nbsp;8.01 Other Events." -->
<DIV align="left"><A NAME="000"></A></DIV>

<P align="left" style="font-size: 10pt"><B>Item&nbsp;8.01 Other Events.</B>


<P align="left" style="font-size: 10pt">On December&nbsp;21, 2004, Epimmune Inc. issued a press release providing an update of ongoing clinical
development programs with its EP-2101 therapeutic cancer vaccine and its EP-1090 therapeutic HIV
vaccine.

<!-- link2 "Item&nbsp;9.01 Financial Statements and Exhibits." -->
<DIV align="left"><A NAME="001"></A></DIV>

<P align="left" style="font-size: 10pt"><B>Item&nbsp;9.01 Financial Statements and Exhibits.</B>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">

<!-- Begin Table Head --><TR valign="bottom">
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="94%">&nbsp;</TD>
</TR>

<!-- End Table Head -->

<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press Release of Epimmune Inc. dated December&nbsp;21, 2004.</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<!-- link1 "SIGNATURES" -->
<DIV align="left"><A NAME="002"></A></DIV>

<P align="center" style="font-size: 10pt"><B>SIGNATURES</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">

<!-- Begin Table Head --><TR valign="bottom">
    <TD width="51%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
</TR>

<!-- End Table Head -->

<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>EPIMMUNE INC.</B></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Date: December&nbsp;21, 2004
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Robert De Vaere</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><HR size="1" noshade>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Robert De Vaere</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Vice President, Finance and Administration,</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Chief Financial Officer and Secretary</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><I>(Principal Accounting Officer and Officer duly
authorized to sign this report on behalf of the
Registrant)</I></TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<!-- link1 "INDEX TO EXHIBITS" -->
<DIV align="left"><A NAME="003"></A></DIV>

<P align="center" style="font-size: 10pt"><B>INDEX TO EXHIBITS</B>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">

<!-- Begin Table Head --><TR valign="bottom">
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="94%">&nbsp;</TD>
</TR>

<!-- End Table Head -->

<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press Release of Epimmune Inc. dated December&nbsp;21, 2004.</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;
</DIV>
</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a04192exv99w1.txt
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<PAGE>
                                                                    Exhibit 99.1


                                [EPIMMUNE LOGO]
              5820 Nancy Ridge Drive, San Diego, California 92121
                   Phone: (858) 860-2500- Fax: (858) 860-2600

- --------------------------------------------------------------------------------

FOR FURTHER INFORMATION

<TABLE>
<S>                      <C>                                      <C>
AT EPIMMUNE:             AT FINANCIAL RELATIONS BOARD:
Robert De Vaere          Lars Glassen                             Tricia Ross
VP, Finance & Admin.     General Information                      Investor/Analyst Information
& CFO                    (310) 854-8313                           (617) 520-7064
(858) 860-2500           lglassen@financialrelationsboard.com     tross@financialrelationsboard.com
</TABLE>

- --------------------------------------------------------------------------------

FOR IMMEDIATE RELEASE
DECEMBER 21, 2004

    EPIMMUNE PROVIDES UPDATE ON CANCER AND HIV CLINICAL DEVELOPMENT PROGRAMS

SAN DIEGO, DECEMBER 21, 2004 - EPIMMUNE INC. (NASDAQ: EPMN) today provided an
update of ongoing clinical development programs with its EP-2101 therapeutic
cancer vaccine and its EP-1090 therapeutic HIV vaccine.

CANCER VACCINE CLINICAL DEVELOPMENT

Epimmune conducted two Phase 1 clinical trials of its EP-2101 cancer vaccine
candidate at seven clinical sites in the U.S. One trial enrolled stage IIB/IIIA
non-small cell lung (NSCL) cancer patients, and the other trial enrolled stage
III colorectal cancer patients. The cancer vaccine candidate used in these
trials is constructed of nine cytotoxic T lymphocyte (CTL) epitopes from four
tumor associated antigens (TAA); these include two native epitopes from the
human TAA, and seven analog epitopes, which are native epitopes modified by
proprietary Epimmune technology. Tolerance to TAA, which is a failure of the
immune system to recognize the cancer as diseased tissue, can be broken by using
these analog epitopes, which are designed to enhance the potency of the T cell
response. The vaccine candidate also includes Epimmune's proprietary, synthetic,
universal helper T lymphocyte (HTL) epitope, PADRE(R), which is designed to
enhance the magnitude and duration of cellular immune responses. Patients
enrolled in the trials previously had surgery to remove all detectable cancer
cells and, as a result, were generally expected to have normal immune system
function. Each patient who completed the trial received six injections of the
vaccine at three-week intervals. Primary endpoints of the trials were safety and
immunogenicity as measured by the quantity and breadth of CTL generated.

Analysis of these two Phase 1 studies of EP-2101 is now complete. Data from
sixteen patients with either stage IIB/IIIA NSCL or stage III colorectal cancer,
who completed the full course of vaccine treatment, showed that EP-2101:

- -     was safe and well tolerated;
- -     was immunogenic - defined as inducing a response to at least one epitope
      included in the vaccine - in approximately 94% of the treated patients;
- -     induced a multi-epitope response with approximately four vaccine epitopes
      being the average number recognized by the treated patients; 50% of the
      treated patients responded to at least five of the nine epitopes included
      in the vaccine; and


Financial Relations Board serves as financial relations counsel to this company,
  is acting on the company's behalf in issuing this bulletin and is receiving
    compensation therefor. The information contained herein is furnished for
     informational purposes only and is not to be construed as an offer to
                            buy or sell securities.
<PAGE>
Epimmune Inc.
Page 2 of 5


- -     induced a response in 69% of the patients to the PADRE(R) epitope included
      in the vaccine, raising HTL responses thought to be useful to support the
      anti-tumor activity mediated by CTL.

Based on this safety and immunogenicity data, as planned, the Company filed an
amendment to its Investigational New Drug application (IND) and has begun the
process of enrolling patients in a Phase 2 study of patients with late stage
NSCL cancer.

The goal of this Phase 2 study is to correlate overall survival and clinical
benefit to patients with immunogenicity. It is being conducted in stage IIIB/IV
NSCL cancer patients with advanced disease as a single dose level, open-label
study with six treatments administered at three-week intervals. The primary
endpoints are overall survival and safety. Secondary endpoints are
progression-free survival and vaccine immunogenicity. The study is being
conducted by Epimmune in the United States and is expected to involve between 10
and 12 sites and enroll approximately 84 patients. Enrollment has begun and is
expected to be complete by the end of 2005 with initial data from the study
expected to be available beginning in the second half of 2006.

HIV VACCINE CLINICAL DEVELOPMENT

Epimmune, with sponsorship from the National Institutes of Health (NIH),
conducted a Phase 1 clinical trial of EP-1090, its multi-epitope, DNA vaccine
designed to stimulate CTL responses to HIV. EP-1090 encodes 21 CTL epitopes from
conserved regions of multiple HIV virus proteins. Because these epitopes are
commonly found in the majority of HIV subtypes, they are believed to be crucial
to the fitness of all viral strains, with the result that the virus should be
unable to rapidly mutate away from immune responses targeted by EP-1090. Such
mutation has presented an obstacle to conventional vaccine development. The
vaccine candidate also includes Epimmune's proprietary, synthetic, universal HTL
epitope, PADRE(R), which is designed to enhance the magnitude and duration of
cellular immune responses.

In the Phase 1 trial, EP-1090 was designed to amplify anti-viral responses in
patients who have been receiving multiple anti-retroviral drugs to suppress HIV
replication, which is a regimen termed "highly active anti-retroviral therapy"
or "HAART." The Phase 1 trial was a double blind, placebo-controlled,
dose-escalation safety study, which was conducted in HIV-infected patients at
the University of Colorado Health Sciences Center. Forty patients were enrolled
in the trial and were randomized into four groups which received intramuscular
doses of 0.5, 1, 2 or 4 mg of vaccine or placebo at 0, 4, 8, and 16 weeks. A
secondary objective of the study was to assess the immunogenicity of the vaccine
as measured by the magnitude and epitope breadth of the patients' cellular
immune responses.

Based on analysis of the data from the Phase 1 study, no serious adverse events
were observed and disease specific indicators such as CD4+ T cell counts
remained stable, indicating that EP-1090 was safe and well tolerated at all dose
levels.

For the assessment of immunogenicity, or epitope-specific CTL responses, patient
blood samples were tested using two independent in vitro ELISPOT assays which
measure the number of epitope-specific CTL per million peripheral blood
mononuclear cells (PBMC) in the patient samples:

- -     DIRECT ELISPOT: Epitope-specific CTL are detected directly after blood
      draws from the patients. The following results were obtained using direct
      ELISPOT:

      o     2/32 (6%) of vaccine recipients responded to 2 or more epitopes
<PAGE>
Epimmune Inc.
Page 3 of 5


      o     5/32 (15%) of vaccine recipients responded to 1 or more epitopes

- -     RESTIMULATED ELISPOT: After blood draws, the PBMC are incubated in vitro
      for seven days with a pool of the 21 vaccine epitopes prior to detecting
      the epitope-specific CTL. This incubation expands the population of
      epitope-specific cells, thereby increasing assay sensitivity. It also may
      simulate the in vivo re-emergence of HIV antigen that occurs when patients
      withdraw from anti-retroviral drug therapy. The following results were
      obtained using restimulated ELISPOT:

      o     9/32 (28%) of vaccine recipients responded to 2 or more epitopes
      o     17/32 (53%) of vaccine recipients responded to 1 or more epitopes
      o     1/8 (12.5%) of placebo recipients responded to 2 or more epitopes

      Because of the small group size, vaccine responses were not statistically
      significant compared to placebo response.

Results from the restimulated ELISPOT assay indicated priming of new CTLs, which
is believed to be required for virus suppression and is not achieved by
conventional vaccines designed to stimulate antibody responses. Based on the
data from the Phase 1 study, the Company plans to amend its IND to open an
additional arm of the Phase 1 study. The goal of this arm, in addition to
demonstrating safety, is to determine whether the immune response can be
enhanced sufficiently to justify continuing to a Phase 2 study. Under the
amended IND, the Company plans to evaluate the use of a needle-free injection
device (NFID) in conjunction with a compressed immunization schedule. Data
presented by other groups indicates that both of these approaches act to
increase the immune response.

The additional evaluation would be conducted in two dose groups consisting of 2
and 4 mgs of vaccine or placebo respectively, assuming the safety profile of
EP-1090 remains favorable. The study arm will involve approximately 16 patients
in each dose group, 12 receiving vaccine and 4 receiving placebo. Total study
duration for each patient, including follow-up, is estimated to be approximately
six months.

The ultimate treatment goal, which would be the subject of a Phase 2 study, is
to allow patients to discontinue HAART for a period of time by using EP-1090 to
stimulate their natural immune suppression of HIV replication.

MANAGEMENT COMMENTS

Dr. Emile Loria, President and CEO of Epimmune said, "We are very pleased with
the progress we have made in our cancer clinical program, particularly the Phase
1 results demonstrating the ability of our proprietary epitope analogs to elicit
a multi-epitope response in a cancer setting where breaking tolerance has always
been a key challenge. The Phase 2 study we have initiated in later stage lung
cancer patients, who continue to have limited treatment options and poor
clinical prognosis, is an important milestone in the continuing development of
our epitope vaccine technology."

Dr. Loria continued, "We also remain committed to finding the most efficient way
to deliver our epitopes in the HIV setting. We believe epitope vaccines
represent a promising approach to dealing with the virus' ability to mutate away
from natural immune responses. Given the complexity of vaccine design and the
alternatives for improving response, we feel there are multiple avenues for
investigation; by expanding our Phase 1 HIV study to explore some of these, we
hope to improve and
<PAGE>
Epimmune Inc.
Page 4 of 5


maximize the vaccine potency before entering a Phase 2 study. We remain
optimistic that we will overcome the tactical difficulties of achieving that
goal."

ABOUT EPIMMUNE INC.

EPIMMUNE INC., based in San Diego, is focused on the development of vaccines
using multiple epitopes to specifically activate the body's immune system.
Epitopes, critical signaling molecules, stimulate the T cell arm of the immune
system to respond to specific regions of cancer cells or infectious agents. By
combining multiple, selected epitopes into a single vaccine candidate, the
immune response can be both targeted and optimized for strength. Epimmune's
therapeutic vaccine candidates have been designed to treat disease by
stimulating the body's immune system to respond aggressively to infections such
as HIV, hepatitis C virus and hepatitis B virus, and tumors such as breast,
colon, lung and prostate. The Company's prophylactic vaccine candidates have
been designed to protect against disease by teaching the body's immune system to
react quickly when exposed to infectious agents. Epimmune's technology can also
be used to identify and potentially eliminate undesirable reactions to
therapeutic drugs or consumer products by modifying specific epitopes to
suppress the unwanted immune response without degrading product efficacy. For
more information on Epimmune, visit www.epimmune.com.

FORWARD-LOOKING STATEMENTS

This press release includes forward-looking statements that reflect Epimmune's
management's current views of future events, including statements regarding the
potential advantages of analog epitopes in cancer vaccines, the ability of the
Company's PADRE(R) technology to enhance the immune response and support
anti-tumor activity, the support provided by the data from the Phase 1 trial of
EP-2101 for the design and implementation of a Phase 2 trial with survival,
immunogenicity and safety endpoints, the support the preliminary data from the
two Phase 1 cancer trials provide for the Company's multi-epitope approach, the
timing for completion of enrollment for the Phase 2 study and the availability
of data from the study, the ability of epitope-based vaccines to treat lung
cancer and colorectal cancer, the intended benefits of the Company's EP HIV-1090
therapeutic vaccine, the ultimate treatment goal for use of EP HIV-1090, the
support the preliminary data from the Company's Phase 1 cancer and HIV trials
provides for the Company's multi-epitope approach to inducing an immune
response, the ability of an epitope-based vaccine to prevent or treat HIV
infection, and the safety and efficacy of epitope-based products in humans.
Actual results may differ materially from the above forward-looking statements
due to a number of important factors such as whether the Company will be able to
enroll the desired number of patients in its Phase 2 NSCL cancer study on
schedule, whether patients enrolled in the Phase 2 study complete the study,
whether the Company will be able to obtain and analyze data from the study by
the second half of 2006, whether results in the Phase 2 study will be consistent
with results from the Phase 1 study, whether there will be a correlation in the
Phase 2 study between overall survival and clinical benefit to patients with
immunogenicity, whether patients with advanced stage cancer will be able to
mount an immune response, whether the Company will be successful in enhancing
the immune response sufficiently in a new arm of its Phase 1 HIV study to
justify continuing to a Phase 2 study, whether in vitro re-stimulation reflects
the levels of CTL activity that could be achieved were the CTL exposed to the
HIV antigens naturally, whether the Company will have sufficient funding
available to support further development of its vaccine candidates, whether the
Company or any of its partners is able to develop pharmaceutical products using
epitopes or analog epitopes, the regulatory approval process, the possibility
that the FDA may comment or raise concerns or questions with respect to any IND
or IND amendment the Company files and, therefore, clinical trials may not begin
when planned, the
<PAGE>
Epimmune Inc.
Page 5 of 5


possibility that the Company's clinical studies may not provide the FDA with
sufficient clinical data to permit proceeding to the next stage of clinical
development of a new drug even though the Company believes it is doing the right
studies based on the protocol, and the possibility that testing may reveal
undesirable and unintended side effects or other characteristics that may
prevent or limit the commercial use of proposed products. These factors are more
fully discussed in the Company's Annual Report on Form 10-K, as amended, filed
with the SEC for the year ended December 31, 2003, the Company's Quarterly
Report on Form 10-Q filed with the SEC for the quarter ended September 30, 2004
and other periodic reports filed with the Securities and Exchange Commission.
Epimmune expressly disclaims any intent or obligation to update these
forward-looking statements, except as required by law.

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
